THE NOCTURIA IMPACT DIARY- A NEW VALIDATED SELF-REPORTED IMPACT ASSESSMENT TOOL

Published Sep 26, 2014
Copenhagen, Denmark - Many people experience waking up several times a night to go to the toilet – a condition called nocturia. Some people fall right back to sleep and are not bothered at all, but others experience a chronic, cumulative interference with sleep with a large impact on quality of life. As a result, researchers from Denmark and the United States developed the Nocturia Impact Diary © to assess the potential impact of nocturia on quality of life and the benefit of treatment. The Nocturia Impact Diary is a questionnaire that includes questions on energy, productivity, mood, low sleep quality, as well as social self-limitations. The development of this questionnaire followed three steps recommended by the FDA as well as the ISPOR PRO guidelines (concepts and assessment): (1) development of a comprehensive concept pool compiled to reflect the important aspects of nocturia experienced by patients; (2) content validity explored in a series of focus group interviews; and (3) psychometric testing to assess the validity, reliability and sensitivity of the diary in a clinical trial setting. “The Nocturia Impact (NI) Diary is the first nocturia impact assessment tool developed in close dialogue with the FDA and in accordance with new patient-reported outcome (PRO) validation guidelines,” said author Dr. Tove Holm-Larsen, PhD, Managing Director of Pharma Evidence and external lecturer at the University of Copenhagen, Denmark.  “The NI Diary has high validity, reliability and sensitivity. It captures the real-life consequences of nocturia and its treatment and should be used in conjunction with the 3-Day Voiding Diary, commonly used for diagnosis of urological diseases.” The full study, “The Nocturia Impact Diary: A Self-Reported Impact Measure to Complement the Voiding Diary,” is published in Value in Health.

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×